IB Acquisition Corp. IBAC

Industrials SIC 8731 - Services-Commercial Physical & Biological Research Nasdaq

are a blank check company formed under the laws of the State of Delaware on July 7, 2020 and which converted to a Nevada corporation

on September 21, 2023. We were formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization

or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination.

Our investment strategy is not specific to any sector; however, the management team and board members believe there are compelling investment

Last close 10.89 2026-09-04
Market cap $54.5M 2026-06-30 share count
52-week range 10.19 - 11.45

Valuation FY2025 figures against the last close

P/S
P/E
P/FCF
EV/EBITDA
Dividend yield
Diluted EPS

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022
SG&A $748.9K$524.0K$6.8K
Operating income -$748.9K-$524.0K-$6.8K
Interest expense $3.0M
Pre-tax income $4.4M$2.5M-$6.8K
Income tax $965.6K$635.5K
Net income $3.4M$1.9M-$6.8K

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022
Cash and equivalents $428.7K$822.8K$52.6K
Total current assets $1.2M$1.2M$52.6K
Total assets $17.1M$119.8M$52.6K
Accounts payable $73.8K$86.7K$8.0K
Total current liabilities $1.8M$722.2K$58.0K
Total liabilities $1.8M$722.2K$58.0K
Retained earnings -$681.7K$1.1M-$8.4K
Total equity -$681.3K$1.1M-$5.4K$1.4K

Cash flow

Fiscal year FY2025FY2024FY2023FY2022
Operating cash flow -$1.3M-$821.0K-$207
Investing cash flow $107.8M-$115.6M
Financing cash flow -$106.1M$117.2M$50.0K
Buybacks $106.1M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-034626.

Others in SIC 8731

TickerCompanyMarket capP/ERevenue growth
IQV IQVIA HOLDINGS INC. $44.69B 34.2x 5.9%
INCY INCYTE CORP $25.32B 19.8x 21.2%
MEDP Medpace Holdings, Inc. $16.50B 38.7x 20.0%
CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. $13.77B -0.9%
ABSI Absci Corp $1.51B -38.2%
OABI OmniAb, Inc. $629.5M -29.3%
NRC NRC HEALTH $476.2M 0.4x -4.0%
MXCT MAXCYTE, INC. $132.1M -5.7%